Equities Research Analysts’ updated eps estimates for Monday, March 9th:
Adobe (NASDAQ:ADBE) had its outperform rating reiterated by analysts at Royal Bank Of Canada. The firm currently has a $430.00 price target on the stock.
argenex (NASDAQ:ARGX) had its outperform rating reissued by analysts at Wedbush. The firm currently has a $1,000.00 price target on the stock.
Portman Ridge Finance (NASDAQ:BCIC) had its neutral rating reissued by analysts at LADENBURG THALM/SH SH.
Benitec Biopharma (NASDAQ:BNTC) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $32.00 price target on the stock.
CytomX Therapeutics (NASDAQ:CTMX) had its buy rating reissued by analysts at Guggenheim. They currently have a $10.00 target price on the stock.
Day One Biopharmaceuticals (NASDAQ:DAWN) had its neutral rating reiterated by analysts at Wedbush. They currently have a $21.50 price target on the stock, down from their previous price target of $30.00.
Doximity (NASDAQ:DOCS) had its outperform rating reissued by analysts at Royal Bank Of Canada. They currently have a $44.00 price target on the stock.
DexCom (NASDAQ:DXCM) had its buy rating reaffirmed by analysts at BTIG Research. The firm currently has a $85.00 price target on the stock.
enGene (NASDAQ:ENGN) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $25.00 price target on the stock.
Evaxion A/S (NASDAQ:EVAX) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $16.00 price target on the stock.
Immuneering (NASDAQ:IMRX) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $11.00 target price on the stock.
Incyte (NASDAQ:INCY) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $135.00 price target on the stock.
Inuvo (NYSEAMERICAN:INUV) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $6.00 target price on the stock.
Jade Biosciences (NASDAQ:JBIO) had its outperform rating reaffirmed by analysts at Wedbush. They currently have a $24.00 target price on the stock.
Maze Therapeutics (NASDAQ:MAZE) had its buy rating reissued by analysts at BTIG Research. BTIG Research currently has a $46.00 price target on the stock.
Medline (NASDAQ:MDLN) had its buy rating reaffirmed by analysts at BTIG Research. The firm currently has a $55.00 target price on the stock.
BiomX (NYSEAMERICAN:PHGE) had its neutral rating reiterated by analysts at HC Wainwright.
Cartesian Therapeutics (NASDAQ:RNAC) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $42.00 price target on the stock.
Scholastic (NASDAQ:SCHL) had its neutral rating reaffirmed by analysts at B. Riley Financial, Inc.. They currently have a $37.00 target price on the stock.
Talkspace (NASDAQ:TALK) had its hold rating reaffirmed by analysts at Needham & Company LLC.
Turtle Beach (NASDAQ:TBCH) had its neutral rating reiterated by analysts at Wedbush. The firm currently has a $14.00 target price on the stock.
Oncology Institute (NASDAQ:TOI) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $5.00 target price on the stock.
Oncology Institute (NASDAQ:TOI) had its buy rating reiterated by analysts at BTIG Research. The firm currently has a $7.00 target price on the stock.
Trevi Therapeutics (NASDAQ:TRVI) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $21.00 price target on the stock.
Valaris (NYSE:VAL) had its neutral rating reaffirmed by analysts at BTIG Research.
Receive News & Ratings for Adobe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adobe Inc and related companies with MarketBeat.com's FREE daily email newsletter.
